Athena Pharmaceutiques Oral Dispersible Tablets

Athena Pharmaceutiques Oral Dispersible Tablets

X

Find Clinical Drug Pipeline Developments & Deals by SemaThera Inc

SemaThera Inc
Developments
Full Screen View

SemaThera Inc

About, Contact Details

EVENTS

Webinars & Exhibitions

Webinars & Exhibitions

PRESENTATION(s)

No Presentations

VIDEO(s)

No Video

DIGITAL CONTENT

3 News

3 News

DEVELOPMENTS

1 Drug(s) in Development

1 Drug(s) in Development

Developments

Filters

×

FILTER:

filter

Company

filter

Sponsor

filter

Country

filter

Therapeutic Area

filter

Study Phase

Active Filter(s):

Filters

Reset Filter

All Developments

Companies By Therapeutic Area

Development Status

SemaThera Inc

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

SemaThera Enters into a Research Collaboration and Exclusive License Agreement with Roche

Details:

The partnership will focus on developing SemaThera’s promising new class of biologicals for the treatment of diabetic retinopathy and other ischemic retinal diseases.

Lead Product(s): Undisclosed

Therapeutic Area: Ophthalmology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Undisclosed

Partner/Sponsor/Collaborator: F. Hoffmann-La Roche

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration March 23, 2021

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY